ZYME

Business Context and Reporting Period

Zymeworks Inc. (ZYME) is a global biotechnology company focused on a royalty-driven asset aggregation strategy, managing a portfolio of licensed healthcare assets and developing novel biotherapeutics. This Form 10-Q covers the quarterly period ended June 30, 2026. The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by 91% year-over-year for both the three and six-month periods. The decline is primarily due to the absence of significant non-recurring collaboration revenue recognized in 2025, including a $20.0 million milestone from BeOne, $18.3 million of deferred revenue recognition, and a $7.5 million option exercise fee from Bristol-Myers Squibb.
• Net Loss Increase: Net loss widened significantly compared to the prior year, driven by lower revenue and increased interest expense related to the new royalty financing arrangement.
• Financing Activity: In March 2026, the company entered into a royalty monetization agreement, receiving $250.0 million in proceeds. This created a new liability of approximately $252.6 million and introduced significant non-cash interest expense ($8.7 million for the six months ended June 30, 2026).
• Share Repurchases: The company aggressively repurchased shares, retiring 3.8 million shares in the first half of 2026 under the 2025 and 2026 Repurchase Programs, spending approximately $143.0 million in total.

Guidance, Outlook, and Strategic Developments

• Proposed Acquisition of Theravance: On June 28, 2026, Zymeworks entered into a definitive agreement to acquire Theravance Biopharma, Inc. The deal involves cash consideration of $17.00 per share plus Contingent Value Rights (CVRs). The transaction is expected to close in the second half of 2026, subject to regulatory approval and shareholder votes. Financing will include cash on hand and a committed $350 million debt facility from OMERS Life Sciences.
• Royalty Monetization: The company sold 30% of future royalties from Ziihera (zanidatamab-hrii) to Royalty Pharma for $250 million. Zymeworks retains 70% of royalties and all milestone payments. The loan bears a fixed interest rate with an estimated effective interest rate of 10.7%.
• Ziihera (Zanidatamab) Progress: The FDA granted Priority Review for Ziihera in combination with chemotherapy for first-line HER2+ gastroesophageal adenocarcinoma (GEA), with a PDUFA date of August 25, 2026. Approval could trigger a $250 million milestone payment from Jazz Pharmaceuticals.
• Liquidity Outlook: Management expects existing cash and marketable securities ($322.5 million) to fund operations for at least the next 12 months, excluding potential milestone receipts or the completion of the Theravance acquisition.

Investor Verification Checklist

• Theravance Acquisition Status: Verify the timeline and conditions for closing the Theravance merger, specifically HSR Act clearance and the Theravance shareholder vote.
• Ziihera Regulatory Decision: Monitor the FDA decision on the August 25, 2026 PDUFA date for first-line GEA approval, which is critical for triggering the $250 million milestone.
• Royalty Financing Terms: Review the specific covenants and repayment triggers in the Royalty Pharma agreement, noting the non-recourse nature but potential acceleration events.
• Debt Financing for Acquisition: Confirm the final terms and closing of the $350 million debt commitment from OMERS Life Sciences.
• Share Count Impact: Assess the dilution impact of the Theravance acquisition (issuance of CVRs) versus the ongoing share repurchase program.